Twitxy Saved

Ed Livingston

Verified account This account is verified. Learn more

@ehlJAMA

Deputy Editor for Clinical Reviews and Education @JAMA_Current Host JAMA Clinical Reviews from 2012-2021. Professor of Surgery, UCLA
Los Angeles Joined July 2011
8K Following 11K Followers 8.8K Posts

Latest posts 5

Pinned post

Ed Livingston Verified account @ehlJAMA
NO ASSOCIATION BETWEEN PREPROCEDURAL FASTING AND WITNESSED PULMONARY ASPIRATION
A SYSTEMATIC REVIEW AND META-ANALYSIS

I want to bring to everyone's attention the publication of an article we have been working on for some time.

Ever been annoyed by having cases cancelled because a patient ate recently? I had this happen a couple of years ago. This motivated me to look at the preoperative fasting literature.

I was surprised to learn how little actual evidence there is to support fasting policies.

In our recent publication we point out that 1) aspiration rates are no different now than they were before fasting was imposed before administering anesthesia 2) The studies used in fasting research use surrogate outcomes that have never been shown to be relevant to human aspiration events.

See the article published in Surgery (@SurgJournal) here:

sciencedirect.com/science/articl…

There is a pressing need to rethink preoperative fasting policies. New studies are needed that employ proper endpoints to provide guidance for how long patients really need to fast. My guess is, not very long.
48 replies 219 reposts 798 likes 276K views View on X
Ed Livingston Verified account @ehlJAMA
Independent appraisal of nemolizumab (NEMLUVIO) in the OLYMPIA & ARCADIA trials. Large itch reductions in prurigo nodularis; selective practice change supported for AD and PN. Full technical assessment: evidenceappraisal.substack.com/p/evidence-app…

#AtopicDermatitis #PrurigoNodularis #EvidenceBasedMedicine
evidenceappraisal.substack.com Evidence Appraisal: Nemolizumab for Prurigo Nodularis (OLYMPIA 1) Direct-to-Consumer Drug Advertisements: The Evidence
Ed Livingston Verified account @ehlJAMA
Nemolizumab (NEMLUVIO) for prurigo nodularis & atopic dermatitis: independent appraisal of the pivotal OLYMPIA 1 & 2 and ARCADIA trials.

Large absolute itch benefit in PN (58% vs 17% at week 16). Selective use supported — not a first-line replacement for existing options.

Full 43-criterion technical assessment inside.

Evidence summary for OLYMPIA 1:

evidenceappraisal.substack.com/p/evidence-app…

#AtopicDermatitis #PrurigoNodularis #EvidenceBasedMedicine
evidenceappraisal.substack.com Evidence Appraisal: Nemolizumab for Prurigo Nodularis (OLYMPIA 1) Direct-to-Consumer Drug Advertisements: The Evidence
Ed Livingston Verified account @ehlJAMA
An oldy but goody. An Evidence Appraisal of the often cited Surgical Checklist article. When assessed in a sructured way, it falls short-short enough that it probably should not have driven policy as much as it did-especially since a higher quality study showed that checklists did not reduce surgical complications. Stay tuned for that one...

See The Evidence Appraisal on Substack

evidenceappraisal.substack.com/p/a-surgical-s…

#surgery #safety